• Bleomycin Sulfate: Applied Fibrosis Workflows

  2026-08-18

  Build reproducible DNA-damage and pulmonary fibrosis models with Bleomycin Sulfate, from concentration-finding in cultured cells to pathway-resolved animal studies. This guide connects practical assay design with mitochondrial IRF3, mitophagy, ferroptosis, and TGF-β-driven fibrosis biology.

• Mithramycin A: Sp1 Assay Workflows & Troubleshooting

  2026-08-17

  Mithramycin A provides a practical transcription-perturbation tool for testing G-C-rich regulatory programs, including c-myc and Sp1-linked responses. This workflow-focused guide covers stock preparation, dose and time-course design, cardiac-model translation, assay controls, and troubleshooting for cancer biology research.

• Mithramycin A: From DNA Binding to Assay Design

  2026-08-17

  Mithramycin A is an anticancer antibiotic that converts G-C-rich DNA recognition into a powerful experimental probe of transcription. This article explains how to interpret its effects alongside the miR-24-3p/Sp1/PI3K findings and design more discriminating cancer biology research assays.

• PPACK Dihydrochloride: Thrombin Research Guide

  2026-08-16

  PPACK Dihydrochloride is an irreversible thrombin inhibitor for mechanistic coagulation and platelet studies. Its reported Ki of 0.24 nM for human α-thrombin supports use in thrombin inhibition assay design, while separate NF449 evidence should not be mistaken for PPACK evidence.

• OCT2/MATE1 Inhibition by 5-HT3 Antagonists

  2026-08-15

  George and colleagues used complementary transporter-expressing cell models to compare how five 5-HT3 antagonists affect renal OCT2- and MATE1-mediated cation transport. The results identify compound- and transporter-dependent inhibition, supporting closer evaluation of renal secretion and potential drug–drug interactions involving cationic medicines.

• WM-8014 for Reproducible Cell Assays

  2026-08-14

  Learn how WM-8014 (SKU A8779) can help distinguish cytostatic responses from general cytotoxicity in viability, proliferation, and senescence experiments. This scenario-driven guide covers mechanism, assay design, formulation constraints, interpretation, and practical product-selection criteria.

• MEK/ERK, c-Myc, and TERT in Human Stem Cells

  2026-08-14

  This bioRxiv study identifies a regulatory circuit in which MEK1/2–ERK signaling and c-Myc:MAX cooperate to keep the TERT promoter active in human embryonic stem cells. Its central mechanistic insight is that loss of either kinase signaling or c-Myc:MAX activity permits polycomb-associated H3K27me3 accumulation, providing a chromatin-level explanation for reduced TERT transcription.

• Dimethyloxalylglycine (DMOG) Protocol Guide

  2026-08-13

  Dimethyloxalylglycine (DMOG) is a cell-permeable PHD inhibitor used to stabilize HIF-1α and model hypoxia-related signaling under controlled experimental conditions. It is appropriate for research on oxygen sensing, hypoxia responses, and inflammation, but it is not intended for diagnostic, therapeutic, or medical use.

• Panobinostat (LBH589): Mechanism and Research Workflow

  2026-08-13

  Panobinostat, also called LBH589, is a hydroxamic acid-based broad-spectrum HDAC inhibitor used to study histone acetylation, apoptosis, and cancer-cell drug resistance. Product information reports low-nanomolar activity in selected leukemia-cell assays and tumor-growth inhibition in an intraperitoneal xenograft model, but assay conditions and model details must be checked before quantitative comparison.

• Pseudo-UTP for mRNA Synthesis Workflows

  2026-08-12

  Pseudo-UTP enables controlled pseudouridine substitution during in vitro transcription, supporting RNA stability enhancement, translation studies, and immune-response investigations. This practical guide covers reaction setup, analytical confirmation, application-specific benchmarking, and troubleshooting for reproducible modified RNA production.

• c-Myc Tag Peptide A6003: Assay Guide

  2026-08-12

  The c-Myc tag peptide is a synthetic competitive reagent for immunoassays that use anti-c-Myc antibodies. A6003 supports displacement of c-Myc-tagged fusion proteins, but it is not a cellular c-MYC inhibitor or a therapeutic product.

• Selective Autophagy Tunes IRF3 Stability and IFN

  2026-08-11

  The reference study identifies a virus-load-sensitive checkpoint in which CALCOCO2/NDP52-dependent selective autophagy controls IRF3 turnover, while PSMD14 preserves IRF3 through deubiquitination. These findings connect ubiquitin-chain editing with autophagic cargo selection and clarify how antiviral interferon production is balanced against excessive immune activation.

• Reelin–SFK Signaling in Ketamine Response

  2026-08-11

  The reference study shows that intact Reelin–Apoer2–Src family kinase signaling is required for ketamine-induced hippocampal synaptic plasticity and behavioral effects in mice. Its key contribution is to identify baseline NMDA receptor function, rather than an acute increase in Reelin signaling, as a permissive factor that may help explain variable ketamine responsiveness.

• 10058-F4 Workflows for c-Myc Research

  2026-08-10

  Build mechanism-focused cancer experiments with 10058-F4, from c-Myc/Max disruption and apoptosis assay design to leukemia, prostate, and exploratory telomerase workflows. Practical dosing, solvent handling, controls, and troubleshooting help distinguish pathway-specific biology from formulation or assay artifacts.

• Entecavir: From Potency to Resistance-Aware Translation

  2026-08-09

  Entecavir, also known as BMS200475, is more than a potent HBV replication inhibitor: its translational value depends on how researchers connect polymerase inhibition, prior nucleos(t)ide exposure, resistance surveillance, and clinically relevant endpoints. This thought-leadership guide turns mechanistic and resistance evidence into a practical framework for chronic hepatitis B research and development.

11577 records 1/772 page Next 12345 下5页 Last page